FREQUENCY OF ELEVATED HEPATOCELLULAR CARCINOMA (HCC) BIOMARKERS (AFP, AFP-L3, AND DCP) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)AND ADVANCED FIBROSIS WITH AND WITHOUT HCC

被引：0
|
作者：
Sterling, Richard K. [1 ]
Wright, Elizabeth C. [2 ]
Morgan, Timothy R. [3 ]
Seeff, Leonard B. [2 ]
Hoefs, John C. [4 ]
Di Bisceglie, Adrian M. [5 ]
Dienstag, Jules L. [6 ]
Lok, Anna S. [7 ]
机构：
[1] Virginia Commonwealth Univ, Div Gastroenterol & Hepatol, Richmond, VA USA
[2] NIDDK, NIH, Bethesda, MD USA
[3] VA Long Beach Healthcare Syst, Long Beach, CA USA
[4] Univ Calif Irvine, Ann Arbor, MI USA
[5] St Louis Univ, St Louis, MO 63103 USA
[6] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA
[7] Univ Michagan, Ann Arbor, MI USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
18
引用
收藏
页码：328A / 328A
页数：1
相关论文
共 50 条
  • [1] Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
    Nunez, K.
    Sandow, T.
    Thevenot, P.
    Cohen, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 492 - 493
  • [2] Biomarkers AFP in combination with AFP-L3 and DCP predicts tumor progression in treatment naive HCC patients
    Nunez, K.
    Sandow, T.
    Thevenot, P.
    Cohen, A.
    TRANSPLANTATION, 2021, 105 (08) : 78 - 79
  • [3] Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C
    Sterling, Richard K.
    Wright, Elizabeth C.
    Morgan, Timothy R.
    Seeff, Leonard B.
    Hoefs, John C.
    Di Bisceglie, Adrian M.
    Dienstag, Jules L.
    Lok, Anna S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (01): : 64 - 74
  • [4] Clinical utility of AFP-L3 glycoforms in risk assessment for hepatocellular carcinoma (HCC) in patients with chronic hepatitis and cirrhosis
    Küper, R
    Satomura, S
    Kanke, F
    Gordon, E
    Schwartz, M
    Sherman, M
    Venook, A
    Jeffers, L
    Sterling, R
    Reddy, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 96 - 96
  • [5] AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study
    Mehta, Neil
    Kotwani, Prashant
    Norman, Joshua
    Shui, Amy
    Li, Po-Yi
    Saxena, Varun
    Chan, Wesley
    Yao, Francis Y.
    LIVER TRANSPLANTATION, 2023, 29 (10) : 1041 - 1049
  • [6] TUMOR BIOMARKERS AFP-L3 AND DCP PREDICT WAITLIST DROPOUT IN HCC PATIENTS AWAITING LIVER TRANSPLANT
    Kotwani, Prashant
    Yao, Francis
    Mehta, Neil
    HEPATOLOGY, 2020, 72 : 655A - 656A
  • [7] Phase 2 validation of AFP, DCP and AFP-L3 in early stage hepatocellular carcinoma
    Marrero, Jorge A.
    Llovet, Josep M.
    Nguyen, Mindie
    Befeler, Alex
    Roberts, Lewis R.
    Reddy, Rajender R.
    Harnois, Denise
    Normolle, Daniel
    Hui, Ying
    Dalhgren, Jackie
    Chia, David
    Lok, Anna S.
    Wagner, Paul D.
    Feng, Ziding
    Schwartz, Myron
    CANCER BIOMARKERS, 2008, 4 (03) : 183 - 183
  • [8] The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States
    Tayob, Nabihah
    Kanwal, Fasiha
    Alsarraj, Abeer
    Hernaez, Ruben
    El-Serag, Hashem B.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (02) : 415 - 423.e4
  • [9] THE PERFORMANCE OF AFP, AFP-3, DCP AS BIOMARKERS FOR DETECTION OF HEPATOCELLULAR CARCINOMA (HCC). A PHASE 3 BIOMARKER STUDY IN THE UNITED STATES
    Tayob, Nabihah
    Kanwal, Fasiha
    Alsarraj, Abeer
    Hernaez, Ruben
    El-Serag, Hashem B.
    HEPATOLOGY, 2021, 74 : 107A - 108A
  • [10] AFP-L3 improves AFP performance in the follow up for the development of hepatocellular carcinoma in chronic hepatitis patients
    Antonakis, P.
    Konstadoulakis, M.
    Kataki, A.
    Roayaie, S.
    Schwartz, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
12345